Tuesday, November 19, 2024 8:14:19 AM
Based on the research I did, there are several approved suppliers of the active pharmaceutical ingredient (API) for Vyvanse (lisdexamfetamine dimesylate) for US drug manufacturers. Here are the key approved suppliers:
Major Approved API Suppliers
Noramco (United States)
Chr. Olesen Group (Denmark)
Embio Limited (India)
Additional Potential Suppliers
While not explicitly confirmed as approved for the US market, these companies are also listed as manufacturers or suppliers of lisdexamfetamine API:
Veranova
Cohance Lifesciences
Tofigh Daru
Alkem Laboratories
Cambrex Corporation
Chattem Chemicals, Inc.
Mallinckrodt Pharmaceuticals
Siegfried AG
Key Details
Noramco, based in the United States, specializes in controlled substance development and manufacturing, including APIs for both opioid and non-opioid products.
Chr. Olesen Group is a European company with a global distribution business and API manufacturing facilities.
Embio Limited is an Indian manufacturer that has been listed as a supplier of lisdexamfetamine API.
Several of these companies have active US Drug Master Files (DMFs) for lisdexamfetamine, indicating their readiness to supply the US markets.
It's important to note that while these companies are listed as manufacturers or suppliers, drug manufacturers in the US would need to ensure that their specific API source is approved by the FDA for use in their generic formulations. The availability of multiple suppliers is expected to increase accessibility and potentially help alleviate shortages of ADHD medications in the US market.
Based on the information that I found, US drug manufacturers do not necessarily need to be domestic suppliers to submit a Drug Master File (DMF) to the FDA.
DMF submission is voluntary and not required by law or FDA regulation.
Both domestic and foreign manufacturers can submit DMFs to the FDA.
However, there is a distinction between domestic and foreign DMF holders:
Domestic DMF holders do not need to appoint a US agent or representative.
Foreign DMF holders are encouraged to engage a US agents.
The FDA accepts DMFs from manufacturers worldwide, as long as they meet the necessary requirements and follow the submission guidelines.
The main purpose of a DMF is to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
DMFs can be submitted for various components of drug manufacturing, including active pharmaceutical ingredients (APIs), excipients, packaging materials, and more.
While US drug manufacturers can certainly be domestic suppliers, it is not a requirement for submitting a DMF to the FDA. The key factor is meeting the FDA's guidelines and requirements for DMF submission, regardless of the manufacturer's location.
https://www.fda.gov/drugs/guidances-drugs/drug-master-files-guidelines
I am not an expert in this field. This is just information I found that may be helpful....I am not disagreeing or challenging anyone's research, just trying to help the ELTP team. 😄
Major Approved API Suppliers
Noramco (United States)
Chr. Olesen Group (Denmark)
Embio Limited (India)
Additional Potential Suppliers
While not explicitly confirmed as approved for the US market, these companies are also listed as manufacturers or suppliers of lisdexamfetamine API:
Veranova
Cohance Lifesciences
Tofigh Daru
Alkem Laboratories
Cambrex Corporation
Chattem Chemicals, Inc.
Mallinckrodt Pharmaceuticals
Siegfried AG
Key Details
Noramco, based in the United States, specializes in controlled substance development and manufacturing, including APIs for both opioid and non-opioid products.
Chr. Olesen Group is a European company with a global distribution business and API manufacturing facilities.
Embio Limited is an Indian manufacturer that has been listed as a supplier of lisdexamfetamine API.
Several of these companies have active US Drug Master Files (DMFs) for lisdexamfetamine, indicating their readiness to supply the US markets.
It's important to note that while these companies are listed as manufacturers or suppliers, drug manufacturers in the US would need to ensure that their specific API source is approved by the FDA for use in their generic formulations. The availability of multiple suppliers is expected to increase accessibility and potentially help alleviate shortages of ADHD medications in the US market.
Based on the information that I found, US drug manufacturers do not necessarily need to be domestic suppliers to submit a Drug Master File (DMF) to the FDA.
DMF submission is voluntary and not required by law or FDA regulation.
Both domestic and foreign manufacturers can submit DMFs to the FDA.
However, there is a distinction between domestic and foreign DMF holders:
Domestic DMF holders do not need to appoint a US agent or representative.
Foreign DMF holders are encouraged to engage a US agents.
The FDA accepts DMFs from manufacturers worldwide, as long as they meet the necessary requirements and follow the submission guidelines.
The main purpose of a DMF is to provide confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
DMFs can be submitted for various components of drug manufacturing, including active pharmaceutical ingredients (APIs), excipients, packaging materials, and more.
While US drug manufacturers can certainly be domestic suppliers, it is not a requirement for submitting a DMF to the FDA. The key factor is meeting the FDA's guidelines and requirements for DMF submission, regardless of the manufacturer's location.
https://www.fda.gov/drugs/guidances-drugs/drug-master-files-guidelines
I am not an expert in this field. This is just information I found that may be helpful....I am not disagreeing or challenging anyone's research, just trying to help the ELTP team. 😄
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
